

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/006157

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/60 C12N9/88 C12N1/21 C12P13/06 C12P13/08 C12Q1/68 //(C12N1/21,C12R1:00) According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C12P C12Q Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, EMBL		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 108 790 A (KYOWA HAKKO KOGYO KK) 20 June 2001 (2001-06-20) page 220; table 1 claims 1,29 sequences 3458,6958	1-4
X	EP 0 356 739 A (AJINOMOTO KK) 7 March 1990 (1990-03-07) abstract page 2, line 36 - line 40 page 3, line 31 - line 39 ----- -/-	1-9
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the International filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the International filing date but later than the priority date claimed *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the International search 15 September 2004		Date of mailing of the International search report 24/09/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Huse, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/006157

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 436 886 A (KERNFORSCHUNGSANLAGE JUELICH) 17 July 1991 (1991-07-17) abstract page 2, line 36 - line 40 page 2, line 48 - line 53 claim 1 claim 5	1-9
X	US 2002/037562 A1 (BELARYEVA ALLA VALENTINOVNA ET AL) 28 March 2002 (2002-03-28) abstract page 2, paragraph 24	5-9
A	WO 02/31158 A (ARCHER DANIELS MIDLAND CO) 18 April 2002 (2002-04-18) the whole document	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2004/006157

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - ☒ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material
 - ☒ In written format
 - ☒ In computer readable form
 - c. time of filing/furnishing
 - ☒ contained in the international application as filed
 - ☒ filed together with the international application in computer readable form
 - ☐ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/006157

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1108790	A	20-06-2001	EP 1108790 A2	20-06-2001
			JP 2002191370 A	09-07-2002
			US 2002197605 A1	26-12-2002
EP 0356739	A	07-03-1990	JP 2042988 A	13-02-1990
			JP 2748418 B2	06-05-1998
			DE 68925083 D1	25-01-1996
			DE 68925083 T2	05-09-1996
			EP 0356739 A1	07-03-1990
EP 0436886	A	17-07-1991	DE 3942947 A1	27-06-1991
			DE 59005821 D1	30-06-1994
			EP 0436886 A1	17-07-1991
US 2002037562	A1	28-03-2002	RU 2209246 C2	27-07-2003
			CN 1310233 A	29-08-2001
			FR 2804971 A1	17-08-2001
			JP 2001231584 A	28-08-2001
WO 0231158	A	18-04-2002	AU 1314602 A	22-04-2002
			BR 0114532 A	30-12-2003
			CA 2425754 A1	18-04-2002
			EP 1325135 A2	09-07-2003
			WO 0231158 A2	18-04-2002
			US 2002177202 A1	28-11-2002

SEQUENCE LISTING

<110> Degussa AG

5 <120> Feedback Resistant Mutants

<130> 020191 AM

<140>

10 <141>

<160> 12

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 519

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence: modified AHAS

<220>

25 <221> CDS

<222> (1) .. (519)

<400> 1

atg gct aat tct gac gtc acc cgc cac atc ctg tcc gta ctc gtt cag 48

30 Met Ala Asn Ser Asp Val Thr Arg His Ile Leu Ser Val Leu Val Gln

1

5

10

15

gac gta gac gat gac ttt tcc cgc gta tca ggt atg ttc acc cga cgc 96
 Asp Val Asp Asp Asp Phe Ser Arg Val Ser Gly Met Phe Thr Arg Arg
 20 25 30

5 gca ttc aac ctc gtg tcc ctc gtg tct gca aag acc gaa aca cac ggc 144
 Ala Phe Asn Leu Val Ser Leu Val Ser Ala Lys Thr Glu Thr His Gly
 35 40 45

atc aac cgc atc acg gtt gtt gtc gac gcc gac gag ctc aac att gag 192
 10 Ile Asn Arg Ile Thr Val Val Val Asp Ala Asp Glu Leu Asn Ile Glu
 50 55 60

cag atc acc aag cag ctc aac aag ctg atc ccc gtg ctc aaa gtc gtg 240
 Gln Ile Thr Lys Gln Leu Asn Lys Leu Ile Pro Val Leu Lys Val Val
 15 65 70 75 80

cga ctt gat gaa gag acc act atc gcc cgc gca atc atg ctg gtt aag 288
 Arg Leu Asp Glu Glu Thr Thr Ile Ala Arg Ala Ile Met Leu Val Lys
 85 90 95

20 gtc tct gcg gac agc acc aac cgt ccg cag atc gtc gac gcc gcg aac 336
 Val Ser Ala Asp Ser Thr Asn Arg Pro Gln Ile Val Asp Ala Ala Asn
 100 105 110

25 atc ttc cgc gcc cga gtc gtc gac gtg gct cca gac tct gtg gtt att 384
 Ile Phe Arg Ala Arg Val Val Asp Val Ala Pro Asp Ser Val Val Ile
 115 120 125

gaa tcc aca ggc acc cca ggc aag ctc cgc gca ctg ctt gac gtg atg 432
 30 Glu Ser Thr Gly Thr Pro Gly Lys Leu Arg Ala Leu Leu Asp Val Met
 130 135 140

gaa cca ttc gga atc cgc gaa ctg atc caa tcc gga cag att gca etc 480
 Glu Pro Phe Gly Ile Arg Glu Leu Ile Gln Ser Gly Gln Ile Ala Leu
 145 150 155 160

5 aac cgc ggt ccg aag acc atg gct ccg gcc aag atc taa 519
 Asn Arg Gly Pro Lys Thr Met Ala Pro Ala Lys Ile
 165 170

10 <210> 2
 <211> 173
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence: modified AHAS

15
 <400> 2
 Met Ala Asn Ser Asp Val Thr Arg His Ile Leu Ser Val Leu Val Gln
 1 5 10 15

20 Asp Val Asp Asp Asp Phe Ser Arg Val Ser Gly Met Phe Thr Arg Arg
 20 25 30

Ala Phe Asn Leu Val Ser Leu Val Ser Ala Lys Thr Glu Thr His Gly
 35 40 45

25 Ile Asn Arg Ile Thr Val Val Val Asp Ala Asp Glu Leu Asn Ile Glu
 50 55 60

Gln Ile Thr Lys Gln Leu Asn Lys Leu Ile Pro Val Leu Lys Val Val
 30 65 70 75 80

Arg Leu Asp Glu Glu Thr Thr Ile Ala Arg Ala Ile Met Leu Val Lys
 85 90 95

Val Ser Ala Asp Ser Thr Asn Arg Pro Gln Ile Val Asp Ala Ala Asn
100 105 110

Ile Phe Arg Ala Arg Val Val Asp Val Ala Pro Asp Ser Val Val Ile
5 115 120 125

Glu Ser Thr Gly Thr Pro Gly Lys Leu Arg Ala Leu Leu Asp Val Met
130 135 140

10 Glu Pro Phe Gly Ile Arg Glu Leu Ile Gln Ser Gly Gln Ile Ala Leu
145 150 155 160

Asn Arg Gly Pro Lys Thr Met Ala Pro Ala Lys Ile
165 170

15

<210> 3
<211> 519
<212> DNA

20 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: modified AHAS

25 <220>
<221> CDS
<222> (1)..(519)

<400> 3

30 atg gct aat tct gac gtc acc cgc cac atc ctg tcc gta ctc gtt cag 48
Met Ala Asn Ser Asp Val Thr Arg His Ile Leu Ser Val Leu Val Gln
1 5 10 15

gac gta gac ggt gac ttt tcc cgc gta tca ggt atg ttc acc cga cgc 96
 Asp Val Asp Gly Asp Phe Ser Arg Val Ser Gly Met Phe Thr Arg Arg
 20 25 30

5 gca ttc aac ctc gtg tcc ctc gtg tct gca aag acc gaa aca cac ggc 144
 Ala Phe Asn Leu Val Ser Leu Val Ser Ala Lys Thr Glu Thr His Gly
 35 40 45

atc aac cgc atc acg gtt gtt gtc gac gcc gac gag ctc aac att gag 192
 10 Ile Asn Arg Ile Thr Val Val Val Asp Ala Asp Glu Leu Asn Ile Glu
 50 55 60

cag atc acc aag cag ctc aac aag ctg atc ccc gtg ctc aaa gtc gtg 240
 Gln Ile Thr Lys Gln Leu Asn Lys Leu Ile Pro Val Leu Lys Val Val
 15 65 70 75 80

cga ctt gat gaa gag acc act atc gcc cgc gca atc atg ctg gtt aag 288
 Arg Leu Asp Glu Glu Thr Thr Ile Ala Arg Ala Ile Met Leu Val Lys
 85 90 95

20 gtc tct gcg gac agc acc aac cgt ccg cag atc gtc gac gcc gcg aac 336
 Val Ser Ala Asp Ser Thr Asn Arg Pro Gln Ile Val Asp Ala Ala Asn
 100 105 110

25 atc ttc cgc gcc cga gtc gtc gac gtg gct cca gac tct gtg gtt att 384
 Ile Phe Arg Ala Arg Val Val Asp Val Ala Pro Asp Ser Val Val Ile
 115 120 125

gaa tcc aca ggc acc cca ggc aag ctc cgc gca ctg ctt gac gtg atg 432
 30 Glu Ser Thr Gly Thr Pro Gly Lys Leu Arg Ala Leu Leu Asp Val Met
 130 135 140

gaa cca ttc gga atc cgc gaa ctg atc caa tcc gga cag att gca ctc 480
 Glu Pro Phe Gly Ile Arg Glu Leu Ile Gln Ser Gly Gln Ile Ala Leu
 145 150 155 160

5 aac cgc ggt ccg aag acc atg gct ccg gcc aag atc taa 519
 Asn Arg Gly Pro Lys Thr Met Ala Pro Ala Lys Ile
 165 170

10 <210> 4
 <211> 173
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence: modified AHAS

15
 <400> 4
 Met Ala Asn Ser Asp Val Thr Arg His Ile Leu Ser Val Leu Val Gln
 1 5 10 15

20 Asp Val Asp Gly Asp Phe Ser Arg Val Ser Gly Met Phe Thr Arg Arg
 20 25 30

Ala Phe Asn Leu Val Ser Leu Val Ser Ala Lys Thr Glu Thr His Gly
 35 40 45

25 Ile Asn Arg Ile Thr Val Val Val Asp Ala Asp Glu Leu Asn Ile Glu
 50 55 60

Gln Ile Thr Lys Gln Leu Asn Lys Leu Ile Pro Val Leu Lys Val Val
 30 65 70 75 80

Arg Leu Asp Glu Glu Thr Thr Ile Ala Arg Ala Ile Met Leu Val Lys
 85 90 95

Val Ser Ala Asp Ser Thr Asn Arg Pro Gln Ile Val Asp Ala Ala Asn
100 105 110

Ile Phe Arg Ala Arg Val Val Asp Val Ala Pro Asp Ser Val Val Ile
5 115 120 125

Glu Ser Thr Gly Thr Pro Gly Lys Leu Arg Ala Leu Leu Asp Val Met
130 135 140

Glu Pro Phe Gly Ile Arg Glu Leu Ile Gln Ser Gly Gln Ile Ala Leu
10 145 150 155 160

Asn Arg Gly Pro Lys Thr Met Ala Pro Ala Lys Ile
15 165 170

<210> 5
<211> 17
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Primer
25
<400> 5
gcggaggaag tactgcc 17

30 <210> 6
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer

<400> 6

5 caatcagatt aattgctggt ta

22

<210> 7

<211> 26

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer

15

<400> 7

ggacgtagac ggtgacattt cccgcg

26

20 <210> 8

<211> 19

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence:Primer

<400> 8

gtttagaact tggccggag

19

30

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer

5

<400> 9

gatacctgccc acattcacga

20

10 <210> 10

<211> 57

<212> PRT

<213> Corynebacterium glutamicum

15 <400> 10

Met Ala Asn Ser Asp Val Thr Arg His Ile Leu Ser Val Leu Val Gln

1

5

10

15

Asp Val Asp Gly Ile Ile Ser Arg Val Ser Gly Met Phe Thr Arg Arg

20

20

25

30

Ala Phe Asn Leu Val Ser Leu Val Ser Ala Lys Thr Glu Thr His Gly

35

40

45

25 Ile Asn Arg Ile Thr Val Val Val Asp

50

55

<210> 11

30 <211> 53

<212> PRT

<213> S. cinnamomensis

<400> 11

10

Met Ser Thr Lys His Thr Leu Ser Val Leu Val Glu Asn Lys Pro Gly

1 5 10 15

Val Leu Ala Arg Ile Thr Ala Leu Phe Ser Arg Arg Gly Phe Asn Ile

5 20 25 30

Asp Ser Leu Ala Val Gly Val Thr Glu His Pro Asp Ile Ser Arg Ile

35 40 45

10 Thr Ile Val Val Asn

50

<210> 12

15 <211> 57

<212> PRT

<213> Escherichia Coli

<400> 12

20 Met Gln Asn Thr Thr His Asp Asn Val Ile Leu Glu Leu Thr Val Arg

1 5 10 15

Asn His Pro Gly Val Met Thr His Val Cys Gly Leu Phe Ala Arg Arg

20 25 30

25

Ala Phe Asn Val Glu Gly Ile Leu Cys Leu Pro Ile Gln Asp Ser Asp

35 40 45

Lys Ser His Ile Trp Leu Leu Val Asn

30 50 55